AnteoTech Ltd (ASX: ADO) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Anteotech Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $228.57 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.99 billion
Earnings per share -0.005
Dividend per share N/A
Year To Date Return -62.30%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

AnteoTech Ltd (ASX: ADO)
Latest News

A young women pumps her fists in excitement after seeing some good news on her laptop regarding the NRW share price
Share Gainers

Why these 2 ASX All Ordinaries shares are surging more than 20% today

Two ASX technology shares are leading the charge higher today.

Read more »

A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
Healthcare Shares

Why the AnteoTech share price is rocketing 33% today

What did AnteoTech update the ASX with?

Read more »

two laboratory researchers in white coats and gloves sit side by side with scientific equipment and a computer screen conducting medical related research.
Healthcare Shares

Here’s why the Anteotech (ASX:ADO) share price is leaping 6% today

What news did this biotech company deliver today?

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

The AnteoTech (ASX:ADO) share price RAT-tles down 8% following TGA update

The TGA has asked for more clinical data, so further trials will now be conducted.

Read more »

A bright graphic showing neon green and red arrows in a downwards direction with a world map behind them in neon blue
Share Fallers

Why AnteoTech, ASX, CIMIC, and Temple & Webster shares are dropping

These ASX shares are falling on Thursday...

Read more »

Woman holding a rapid antigen test.
Healthcare Shares

Rats! How have AnteoTech (ASX:ADO) shares already gained 30% in February?

AnteoTech is riding on the back of RATs in February...

Read more »

A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
Coronavirus News

Why are ASX COVID test shares climbing today?

COVID-19 tests are in focus again today.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

AnteoTech (ASX:AD) share price surges 15% as COVID-19 RAT race continues

The scientific company's shares have bounced back after a horror start to the week.

Read more »

ADO ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About AnteoTech Ltd

AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its keys areas are Energy and Life ScienceDivision. The company is developing four products named AnteoCoat, AnteoX, AnteoBind, and AnteoRelease, all of these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the Anteo Intellectual property.

ADO Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
20 May 2022 $0.12 $0.00 0.00% 4,471,990 $0.12 $0.12 $0.11
19 May 2022 $0.12 $-0.02 -15.38% 4,813,431 $0.12 $0.13 $0.11
18 May 2022 $0.13 $0.04 42.55% 21,702,289 $0.12 $0.15 $0.11
17 May 2022 $0.09 $0.00 0.00% 983,531 $0.09 $0.10 $0.09
16 May 2022 $0.09 $0.00 0.00% 1,253,492 $0.10 $0.10 $0.09
13 May 2022 $0.10 $0.00 0.00% 668,313 $0.09 $0.10 $0.09
12 May 2022 $0.09 $0.00 0.00% 1,842,160 $0.09 $0.10 $0.09
11 May 2022 $0.09 $0.00 0.00% 4,852,843 $0.09 $0.10 $0.09
10 May 2022 $0.09 $0.00 0.00% 8,737,227 $0.09 $0.10 $0.09
09 May 2022 $0.10 $-0.01 -9.52% 6,803,794 $0.10 $0.11 $0.10
06 May 2022 $0.11 $0.00 0.00% 2,708,258 $0.11 $0.11 $0.10
05 May 2022 $0.11 $0.00 0.00% 3,145,859 $0.11 $0.11 $0.11
04 May 2022 $0.11 $-0.01 -9.09% 7,571,962 $0.11 $0.11 $0.10
03 May 2022 $0.11 $-0.01 -8.70% 3,438,781 $0.11 $0.12 $0.11
02 May 2022 $0.12 $0.00 0.00% 4,679,181 $0.12 $0.12 $0.11
29 Apr 2022 $0.12 $0.00 0.00% 2,124,327 $0.12 $0.12 $0.12
28 Apr 2022 $0.12 $0.00 0.00% 726,790 $0.12 $0.12 $0.12
27 Apr 2022 $0.12 $0.00 0.00% 1,621,743 $0.12 $0.13 $0.12
26 Apr 2022 $0.12 $-0.02 -15.38% 2,797,084 $0.13 $0.13 $0.12
22 Apr 2022 $0.13 $0.00 0.00% 3,487,942 $0.13 $0.14 $0.12
21 Apr 2022 $0.13 $-0.01 -7.14% 5,860,615 $0.14 $0.15 $0.13

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
09 May 2022 Ewen Crouch Buy 250 $27,675
On-market trade.
03 May 2022 Geoffrey Cumming Sell 2 $220,000
On-market trade.
23 Dec 2021 Geoffrey Cumming Sell 500 $108,000
On-market trade.
17 Sep 2021 Glenda McLoughlin Buy 250 $58,750
On-market trade.
02 Aug 2021 Geoffrey Cumming Sell 500 $112,500
On-market trade.
25 May 2021 Geoffrey Cumming Buy 17 $4,515
Participation in share purchase plan.
25 May 2021 Geoffrey Cumming Sell 17 $4,515
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
25 May 2021 John (Jack) Hamilton Sell 24 $6,257
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
25 May 2021 John (Jack) Hamilton Buy 24 $6,257
Participation in share purchase plan.
25 May 2021 Christopher Parker Sell 17 $4,515
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
25 May 2021 Christopher Parker Buy 17 $4,515
Participation in share purchase plan.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Katherine Leslie Woodthorpe Non-Executive Director Sep 2021
Dr Woodthorpe is an experienced Chair and Non-Executive Director serving for 20 years on the boards of a range of organizations including listed entities, government boards and for purpose organizations. She has experience working in a range of innovation-dependent industries including healthcare, renewable energy and environmental and climate science. Katherine also has knowledge of the private equity and venture capital industries in the financial sector as well as working closely with superannuation funds on their alternative investments in the private equity space. For seven years she was the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. Prior to AVCAL, she held a range of management and board positions, in Australia and overseas. Katherine commenced her career initially as a chemist then moved to sales of specialised laboratory equipment into the medical and oil, gas and petrochemical sectors covering the geographies of Europe, Asia and the Middle East before locating permanently to Australia in 1988. Dr Woodthorpe, amongst several positions, is a Non-Executive Director of the Olivia Newton John Cancer Research Institute, Bioplatforms Australia Ltd and Vast Solar Pty Ltd.
Dr Geoffrey James Cumming Non-Executive Director Apr 2009
Dr Cumming has over 20 years experience in the healthcare and biotechnology market. His roles have progressed from pure research to sales and marketing roles through to Managing Director level and Board seats. Previously Managing Director of Roche Diagnostic Systems - Oceania Regional Centre, where he transformed a loss making business to one achieving over 30% compound annual growth over a four year period and the highest profitability levels in Roches global organisation. He was also Managing Director and CEO of an Australian based biotechnology company commercialising a range of products in cancer diagnosis and treatment. During his tenure he was responsible for taking research from Sydney University through to product registration. This involved capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. Geoffrey is a Non-Executive Director of Multiple Sclerosis Research Australia, a not-for profit organisation.
Ms Glenda McLoughlin Non-Executive Director Sep 2021
Ms McLaughlin is an experienced Non-Executive Director with over 25 years' experience as an Investment Banker and Senior Executive working in Australia, Asia, the UK and the US. She has held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. Glenda co-founded listed Australian gas company Metgasco Ltd, where she was Executive Director and Chief Financial Officer for eight years. Ms McLoughlin currently holds the positions of Non-Executive Director with Senex Energy Ltd where she chairs the Audit and Risk Committee and is Chair of SCEGGS Redlands. Ms McLoughlin will also Chair of AnteoTech's Risk Committee.
Mr Richard Shubrick Martin Non-Executive Director Sep 2005
Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.
Mr Ewen Graham Wolseley Crouch Non-Executive ChairmanNon-Executive Director Apr 2022
Mr Crouch is currently Chairman of Corporate Travel Management Limited (ASX: CTD) and serves on the Boards of Bluescope Steel Limited (ASX: BSL) and respected Australian non-profit organisation Jawun. From 1988-2103 Mr Crouch was a partner at Allens. He served as Chairman of Partners for 4 years and held a number of practice leadership and management roles, including 11 years of service on the firm's board. He was previously a Director of Westpac Banking Corporation Limited (ASX: WBC), a director of Mission Australia including seven years as Chairman, a member of the Takeovers Panel, a member of the Commonwealth Remuneration Tribunal and a director of Sydney Symphony Orchestra. His board experience and corporate knowledge, together with his governance, legal and international transaction experience complements well the skillset of the current Board of AnteoTech.
Mr Christopher Parker Executive Director Nov 2019
Mr Parker has 30 years plus of experience in both domestic and international life sciences sector mainly with Roche Diagnostics ("Roche"), an internationally renowned pharmaceutical and diagnostics company. In his final role with Roche, before retiring in late 2017, he was Managing Director for UK & Ireland and Management Centre for European Agents where he had responsibility for all diagnostic products in the Roche portfolio. Prior to this he held various roles in general management, marketing and business development in Canada, Asia and Australia targeting the centralised laboratory, decentralised point-of-care (POC), molecular diagnostics and applied sciences markets. Mr Parker was a previous CEO for AnteoTech between April 2018 and May 2019 and then an Executive Director until November 2019.
Mr Duncan Patrick Cornish Chief Financial OfficerCompany Secretary Feb 2019
Mr Derek Thomson Chief Executive Officer Aug 2019
Derek Thomson Chief Executive Officer
Duncan Patrick Cornish Chief Financial OfficerCompany Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Levenson Investments Pty Ltd <Levenson Investment A/C> 109,315,332 5.55%
First Cape Management Pty Ltd 55,346,154 2.81%
Marcolongo Nominees Pty Ltd <Marcolongo Super Fund A/C> 53,439,928 2.71%
Addison Lake Quality Hire Pty Limited 33,048,603 1.68%
Fossil Super Pty Ltd <Fossil Fund A/C> 32,459,231 1.65%
Jackjen Pty Ltd <J A Hamilton Super Fund A/C> 30,018,593 1.52%
Bond Street Custodians Limited <Antsm1 - D67076 A/C> 29,130,249 1.48%
Computer Visions Pty Ltd <Visionary Invests S/F A/C> 22,132,994 1.12%
BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient DRP> 21,599,216 1.10%
Mr Derek Thomson 21,580,554 1.10%
Marcolongo Nominees Pty Ltd <Marcolongo Family A/C> 20,134,578 1.02%
Mrs Mary Curtis 18,120,900 0.92%
Mr Peter Frederick Kemmis 17,198,314 0.87%
Citicorp Nominees Pty Limited 17,083,422 0.87%
Awo & Cao Investments Pty Ltd <Awo & Cao Family S/F A/C> 15,983,571 0.81%
Stydon Capital Pty Ltd 15,536,780 0.79%
Terry & Linden Deavin Super Pty Ltd <T & L Deavin Sf A/C> 14,600,000 0.74%
Austcorp No 190 Pty Ltd 14,381,945 0.73%
Mr Anthony William Olding & Mrs Caroline Anne Olding 14,091,375 0.72%
Mr Philip Michael Deavin & Mrs Chimene Maree Deavin 13,260,000 0.67%